Abstract
To the Editor: Recently, atenolol has generated interest as an alternative to propranolol in the treatment of infantile hemangioma (IH), due to comparable efficacy and better safety profile, in terms of central nervous system (CNS)-related adverse effects.1,2 Despite the promising benefits of atenolol treatment, its effects on CNS development in children have not been evaluated to date. Theoretically, atenolol, unlike propranolol which is lipophilic, has a hydrophilic structure that prevents it from crossing the blood-brain barrier.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
